From Courtroom to Partnership

Novo Nordisk and Hims & Hers Health have settled their prolonged legal dispute over compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy. The resolution comes not as a simple ceasefire but as a commercial partnership that could fundamentally alter the landscape of GLP-1 weight loss medications and their availability to consumers.

The two companies had been locked in an escalating battle over compounded GLP-1 drugs — pharmacy-made versions of branded medications that are permitted under FDA rules when the branded versions are in shortage. Novo Nordisk had aggressively pursued legal action against telehealth companies and compounding pharmacies offering cheaper semaglutide alternatives, arguing they were infringing on patents and potentially compromising patient safety.

Under the new agreement, Hims will transition from selling compounded semaglutide to offering Novo Nordisk's branded products through its telehealth platform, likely at negotiated prices that fall between the compounded versions' low cost and the full retail price of Ozempic and Wegovy.

What This Means for Patients

The partnership has immediate implications for the millions of Americans who have been using compounded GLP-1 medications as a more affordable alternative to branded products. Ozempic carries a list price of roughly $900 per month without insurance, while compounded versions have been available through telehealth platforms for as little as $200 to $300 per month.

The deal signals that compounded GLP-1s may become harder to obtain. With a major telehealth distributor like Hims shifting to branded products, the market for compounded alternatives shrinks. Other telehealth companies that have built businesses around compounded semaglutide are watching the settlement closely for signals about their own legal exposure.

Patient advocacy groups have expressed concern that the partnership could reduce access to affordable weight loss medications at a time when demand is at an all-time high. Obesity affects more than 40 percent of American adults, and GLP-1 medications have shown unprecedented efficacy in clinical trials, with many patients losing 15 to 20 percent of their body weight.